5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole manufacturers
- UNC9995
-
- $985.00
-
2026-05-11
- CAS:1354030-52-6
- Purity:
- Supply Ability: 10g
|
| | 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole Basic information |
| | 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole Chemical Properties |
| form | Solid | | color | White to off-white |
| | 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole Usage And Synthesis |
| Description | UNC9995 is a β-Arrestin-Biased Dopamine D2 Receptor agonist (β-Arrestin, EC50 = 120 nM; Emax = 88%). | | Uses | UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by JAK/STAT3. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions[1]. | | in vivo | UNC9995 (2 mg/kg/day, i.p, 2 weeks) ameliorates depressive-like behavioral phenotype and improves the loss of astrocytes in the hippocampus in both Chronic social defeated stress (CSDS) model and Chronic unpredictable mild stress (CUMS) model in mouse[1].
| Animal Model: | Chronic unpredictable mild stress (CUMS) mouse model[1] | | Dosage: | 2 mg/kg/d | | Administration: | IP; 2 weeks | | Result: | Improved depressive-like symptoms of CUMS mouse model in WT mice but not Arrb2/ mice. |
| | IC 50 | D2 Receptor | | References | [1] Liu Y, et al. β-Arrestin2-biased Drd2 agonist UNC9995 alleviates astrocyte inflammatory injury via interaction between β-arrestin2 and STAT3 in mouse model of depression. J Neuroinflammation. 2022 Oct 1;19(1):240. DOI:10.1186/s12974-022-02597-6 |
| | 5-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)benzo[d]thiazole Preparation Products And Raw materials |
|